Biotech Archives - Page 55 of 795

3 minute read

Dario Publishes New Peer-Reviewed Study That Deepens The Body Of Evidence That Managing Cardiometabolic Conditions In One Integrated Platform Improves Clinical Outcomes

April 25, 8:47 AM

Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1NEW YORK, April 25, 2024

DRIO

3 minute read

Bausch + Lomb Announces Results From A Clinical Study Of A Novel Daily Nutritional Supplement For Dry Eyes, All Primary Endpoints Achieved

By Benzinga Newsdesk

April 25, 8:43 AM

Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints AchievedBausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live

BLCO

3 minute read

Apollomics Announces Approval Of Vebreltinib In China As A First-In-Class Treatment For Gliomas With MET Fusion Gene

By Benzinga Newsdesk

April 25, 8:42 AM

Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval

APLM

2 minute read

Elicio Therapeutics To Present New Preliminary Data From The Ongoing AMPLIFY-7P Phase 1/2 Study Of ELI-002 7P In Patients With mKRAS-Driven Solid Tumors At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 25, 8:41 AM

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it

ELTX

3 minute read

Vistagen Announces Results From Phase 2A Pilot Study Of PH15 For Improvement Of Psychomotor Impairment Caused By Mental Fatigue

By Benzinga Newsdesk

April 25, 8:40 AM

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participantsPH15 was safe and well-tolerated with an adverse

VTGN

1 minute read

Theriva Biologics To Discuss The Trial Design For VIRAGE – A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 25, 8:34 AM

Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength

TOVX

3 minute read

MediWound To Present New Data From EscharEx Phase II Studies At 3 Wound Care Conferences

By Benzinga Newsdesk

April 25, 8:32 AM

Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned

MDWD

4 minute read

BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer’s Disease And Biomarker Endpoints

By Benzinga Newsdesk

April 25, 8:29 AM

"Bezisterim" has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammationCARSON CITY,

BIVI

3 minute read

AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Wors…

By Benzinga Newsdesk

April 25, 8:09 AM

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161LEVEL UP, a Phase 3b/4

ABBV

1 minute read

Inspira Receives CSA Certification Of Compliance To U.S. Standards For The INSPIRA ART100

By Benzinga Newsdesk

April 25, 8:04 AM

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced that it has received the Canadian Standards Association

IINN